Mucus fishing syndrome (MFS) is a condition characterized by the compulsive and repetitive act of picking one's eyes to remove mucus. While the condition may seem trivial, it can cause significant social and psychological distress.
In this post, we will discuss the causes and symptoms of MFS and treatment options.
However, if you'd like a more detailed guide on this, look at our central blog, Everything About Mucus Fishing Syndrome: Causes, Symptoms, And Treatments.
Causes of Mucus Fishing Syndrome
Dry Eye syndrome
Dry eye syndrome happens when the eyes don't produce enough tears or if they're not of the proper consistency.
This can cause redness, itching, soreness, and a sensation of sand in the eyes. We recommend trying these Best Rated Eye Drops For Dry Eyes.
Allergies
Excess mucus can also be caused by seasonal allergies or allergic responses to cosmetics, dust, pollen, and dander.
Conjunctivitis
Conjunctivitis, also known as pink eye, is an irritation of the conjunctiva. (the transparent membrane that covers the white part of the eye).
Vectors, germs, allergies, and irritants are some possible causes of pink eye, according to the National Eye Institute.
Blepharitis
Blepharitis is an inflammation of the eyelid. It can be caused by a bacterial infection, allergies, or skin disorders such as seborrheic dermatitis.
Dacryocystitis
Dacryocystitis is an infection or blockage of tear ducts that results in severe tearing. The tear duct is a tiny canal that empties the eyes' tears into the nose.
Body-focused Repetitive Behavior (BFRB) Disorder
Mucus fishing syndrome is a body-focused, repetitive behavior disease (BFRBD). Repetitive and purposeful hair, skin, or nail damage is a hallmark of BFRBs.
BFRBs are illnesses characterized by the repetitive and intentional application of damage to one's hair, skin, or nails. To help calm this urge, we suggest trying these teas;
Ways To Prevent Mucus Fishing Syndrome
- Seek treatment for any underlying psychological conditions.
- Follow your doctor's recommendations for eye care.
- Avoid rubbing or touching your eyes unnecessarily.
- If you find yourself compulsively picking at your eyes, make an appointment with an ophthalmologist
With proper care and treatment, it is possible to prevent MFS from causing lasting damage to your eyesight.
Damage Mucus Fishing Syndrome Can Cause
Although the condition is not life-threatening, it can cause serious damage to the eyes. In severe cases, MFS can lead to corneal scarring, vision loss, and even blindness.
The condition most often affects children and adolescents but can also occur in adults. MFS is thought to be caused by a combination of psychological factors, such as anxiety and OCD. Treatment typically involves a combination of therapy and medication. In some cases, surgery may also be necessary.
Mucus Fishing Syndrome can be a considerable problem in personal and professional relationships. It's essential to understand the causes and effects of this syndrome so you can take steps to prevent it.
If you or someone you know is struggling, please reach out for help and read our main blog, Everything About Mucus Fishing Syndrome: Causes, Symptoms, And Treatments, for further details.
And more informative articles like this, check out Ultiblog.com.
Global Dry Eye Syndrome Treatment Market: Overview
Dry eye syndrome (DES) is also known as keratisis sicca and kerato-conjunctivitis sicca. People suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114612/Dry-Eye-Syndrome-Treatment-Market
The two most common types of DES are DES associated with Sjogren syndrome (SS) and DES unassociated with SS. DES can also be classified as aqueous deficiency dry eye and evaporative dry eye disorder. According to TearScience Inc., in 2012, around 86% of the patients in Europe and the U.S. were suffering from DES showed symptoms of Meibomian Gland Dysfunction (MGD, blockage of meibomian glands). The blockage causes less secretion of oil in the tears, which results in evaporation of tears too quickly.
The global dry eye syndrome treatment market is primarily driven by growing geriatric population coupled with high prevalence of dry eye syndrome and growth in awareness about the diagnosis and treatment of the disease. However, the stringent drug approvals, expirations of the blockbuster drugs patents, and lack of skilled ophthalmologists are restraining the growth of DES market. According to National Health and Wellness Survey in 2013, approximately 16.4 million people are suffering from DES, which accounts for 6.8% of the total population of the U.S. Prevalence of DES increases with age, 2.7% for 18 - 34 age group and 18.6% for more than 75 age group were reported to be suffering from DES. The prevalence of DES is higher in women (8.8%) as compared to men (4.5%). According to the National Eye Institute, in the U.S the annual cost of treating DES including prescription drugs is US $3.84 billion.
Global Dry Eye Syndrome Treatment Market: Segmentation
By Product Type
- Cyclosporine
- Oral Corticosteroid
- Artificial Tears
- Omega Supplements
- Punctual Bags
- Removable Bags
- Dissolvable Bags
By Disease Type:
- Evaporative Dry Eye Syndrome
- Aqueous Dry Eye Syndrome
By Product
- Liquid Drops
- Gel
- Liquid Wipes
- Eye Ointment
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114612/Dry-Eye-Syndrome-Treatment-Market
High healthcare expenditure and increasing R&D activities in the DES treatment market is expected to propel growth of DES market in North America
Growing geriatric population coupled with high prevalence of dry eye syndrome owing to lifestyle disorders are contributing factors for the growth of DES market in the North America region.
Asia Pacific region is emerging in DES treatment market due to large pool of patient population. According to the regional population based study published in All India Ophthalmological Society, in 2012, the prevalence of DES was 40.8% with mild symptoms and 31.7% with MGD.
Global dry eye syndrome treatment market is oligopolistic in nature with few players holding majority of the share. Various strategies are adopted by market players such as new product launches, acquisitions, and agreements in order to retain market position. In September, 2017, Johnson and Johnson Vision, acquired TearScience Inc., a medical device manufacturer for treating MGD. This acquisition expanded the company’s eye health portfolio. In April 2017, Allergan received marketing approval from FDA for its TrueTear Intranasal Tear Neurostimulator.
Some of the major players operating in the global dry eye syndrome treatment market are Allergan, Novartis AG., Otsuka Pharmaceutical Co. Ltd., Valent Pharmaceuticals, Johnson and Johnson Vision, Acadia Pharmaceuticals, Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT pharmaceuticals, Novaliq GmBh, and Auven therapeutics.
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114612/Dry-Eye-Syndrome-Treatment-Market
The new research report titled "Dry Eye Syndrome Market, Global Industry Analysis, and Forecast to 2027" gives a detailed analysis and future forecasts of the market.
The report highlights the significant players, including market size, share, and demand, development.
This report further covers the latest trends, technological advancements, and growth opportunities.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the dry eye syndrome market include Allergan, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Valent Pharmaceuticals, Johnson And Johnson Vision, Acadia Pharmaceutical, Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT Pharmaceuticals, Others.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Dry Eye Syndrome Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/dry-eye-syndrome-market/download-sampleMarket DynamicsThe growing emphasis on the treatment of dry eye syndrome due to its severity and its potential to affect one's vision is the critical trend creating several opportunities for market growth.
The increased investment in the R & D of various treatment options will positively impact this market's growth.
